Get the Stockscreener App
1.04
0.95%
-0.01
After Hours:
1.10
0.06
+5.77%
Coherus Biosciences Inc stock is traded at $1.04, with a volume of 1.86M.
It is down -0.95% in the last 24 hours and down -25.18% over the past month.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
See More
Previous Close:
$1.05
Open:
$1.06
24h Volume:
1.86M
Relative Volume:
0.95
Market Cap:
$119.24M
Revenue:
$257.24M
Net Income/Loss:
$-237.89M
P/E Ratio:
-0.3133
EPS:
-3.32
Net Cash Flow:
$-175.17M
1W Performance:
+0.00%
1M Performance:
-25.18%
6M Performance:
-56.49%
1Y Performance:
-72.19%
1-Day Range:
$1.02
$1.095
1-Week Range:
$0.9745
$1.115
52-Week Range:
$0.9735
$3.98
Coherus Biosciences Inc Stock (CHRS) Company Profile
Name
Coherus Biosciences Inc
Sector
Industry
Phone
(650) 649-3530
Address
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Coherus Biosciences Inc Stock (CHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-24-23 | Initiated | Citigroup | Buy |
| May-01-23 | Initiated | Truist | Buy |
| Mar-28-23 | Upgrade | UBS | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Neutral |
| Mar-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-16-20 | Initiated | BofA Securities | Neutral |
| Apr-17-20 | Initiated | SunTrust | Buy |
| Aug-13-19 | Initiated | Mizuho | Buy |
| Aug-02-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-02-19 | Reiterated | Maxim Group | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-07-19 | Initiated | H.C. Wainwright | Buy |
| Aug-28-18 | Initiated | H.C. Wainwright | Buy |
| Mar-09-18 | Reiterated | Maxim Group | Buy |
| Aug-08-17 | Reiterated | JP Morgan | Overweight |
| Jun-13-17 | Reiterated | Maxim Group | Buy |
| May-05-17 | Initiated | BMO Capital Markets | Outperform |
| Oct-19-16 | Initiated | Robert W. Baird | Outperform |
| Sep-07-16 | Initiated | Maxim Group | Buy |
| Jul-27-16 | Initiated | Citigroup | Buy |
| Jan-20-16 | Initiated | Credit Suisse | Outperform |
View All
Coherus Biosciences Inc Stock (CHRS) Latest News
Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now - Yahoo Finance
Wall Street SWOT: Coherus Biosciences stock faces headwinds amid market challenges - Investing.com
Junshi wins European approval for cheaper checkpoint blocker - The Pharma Letter
Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges - Insider Monkey
Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges - Yahoo Finance
CHRS stock touches 52-week low at $1.01 amid market challenges - Investing.com India
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive - Simply Wall St
CHRS (Coherus BioSciences) Debt-to-EBITDA : -10.54 (As of Jun. 2024) - GuruFocus.com
Institutional owners may take dramatic actions as Coherus BioSciences, Inc.'s (NASDAQ:CHRS) recent 12% drop adds to one-year losses - Yahoo Finance
Coherus BioSciences (CHRS) Stock Price, News & Analysis - MarketBeat
HC Wainwright Weighs in on Coherus BioSciences, Inc.'s FY2028 Earnings (NASDAQ:CHRS) - MarketBeat
Coherus shares stumble on supply issue - The Pharma Letter
HC Wainwright Comments on Coherus BioSciences, Inc.'s FY2024 Earnings (NASDAQ:CHRS) - MarketBeat
Baird maintains Coherus outperform stock rating on recent supply hiccup By Investing.com - Investing.com Australia
Coherus BioSciences, Inc. (NASDAQ:CHRS) Has Found A Path To Profitability - Simply Wall St
Baird maintains Coherus outperform stock rating on recent supply hiccup By Investing.com - Investing.com Canada
Baird maintains Coherus outperform stock rating on recent supply hiccup - Investing.com
Coherus BioSciences (NASDAQ:CHRS) Earns Buy Rating from HC Wainwright - MarketBeat
Coherus BioSciences faces UDENYCA supply disruption - Investing.com
Coherus BioSciences, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Coherus BioSciences (NASDAQ:CHRS) Downgraded to "Hold" at StockNews.com - MarketBeat
Coherus BioSciences, Inc. (NASDAQ:CHRS) Short Interest Up 6.0% in August - MarketBeat
Coherus BioSciences (NASDAQ:CHRS) Upgraded to Buy by StockNews.com - MarketBeat
CHRS (Coherus BioSciences) Enterprise Value : $254.6 Mil (As of Aug. 19, 2024) - GuruFocus.com
CHRS stock touches 52-week low at $1.22 amid market challenges - Investing.com
CHRS stock touches 52-week low at $1.22 amid market challenges - Investing.com UK
CHRS (Coherus BioSciences) Dividends per Share : $0.00 (TTM As of Jun. 2024) - GuruFocus.com
UBS Downgrades Coherus BioSciences (CHRS) - MSN
UBS cuts Coherus to neutral, cites limited growth opportunities - MSN
Coherus BioSciences (NASDAQ:CHRS) Stock Rating Lowered by UBS Group - MarketBeat
Coherus BioSciences (NASDAQ:CHRS) Downgraded by UBS Group - Defense World
UBS cuts Coherus shares target amid concerns over future revenue growth - Investing.com
Coherus BioSciences, Inc. (NASDAQ:CHRS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Coherus BioSciences, Inc. (NASDAQ:CHRS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Evaluating Coherus BioSciences: UDENYCA’s Sucess And LOQTORZI’s Prospects (NASDAQ:CHRS) - Seeking Alpha
Vanguard Group Inc. Has $24.09 Million Stock Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World
Coherus BioSciences Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Coherus BioSciences, Inc. (CHRS) Q2 2024 Earnings Call Transcript - Seeking Alpha
Coherus BioSciences: Q2 Earnings Snapshot - CTPost
A quintet of CFO hires at Intra-Cellular, Engrail, Faron, Coherus and Element - BioCentury
Coherus BioSciences: Q2 Earnings Snapshot - Houston Chronicle
Coherus BioSciences: Q2 Earnings Snapshot - San Antonio Express-News
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates - MSN
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update - BioSpace
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Canada Finance
Coherus Biosciences Appoints Bryan McMichael as CFO - TipRanks
Coherus BioSciences: Q2 Earnings Snapshot - The Bakersfield Californian
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S - Simply Wall St
Coherus BioSciences (CHRS) to Release Earnings on Thursday - Defense World
Coherus Biosciences Inc Stock (CHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):